TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23140517

Group type: EXPERIMENTAL
Intervention: Test paste containing 8% arginine and calcium carbonate (elmex sensitive professional desensitizing paste)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control paste: paris white (calcium carbonate)
Number of subjects: 30
Study: 22000343

Group type: EXPERIMENTAL
Intervention: Group I (study group) with vaginal introital defects
Number of subjects: 128

Group type: COMPARATOR
Intervention: Group II (control) without vaginal introital defects
Number of subjects: 128

Group type: COMPARATOR
Intervention: Comparison of Group I and Group II
Number of subjects: 128
Study: 19220493

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents
Number of subjects: 433

Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitors
Number of subjects: 433

Group type: COMPARATOR
Intervention: Nonnucleoside reverse transcriptase inhibitors (NNRTIs), particularly efavirenz
Number of subjects: 433
Study: 17967650

Group type: EXPERIMENTAL
Intervention: Open food challenge (OFC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge (DBPCFC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15005866

Group type: EXPERIMENTAL
Intervention: Spatial memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-spatial memory task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no cognitive task)
Number of subjects: 0
Study: 11338761

Group type: EXPERIMENTAL
Intervention: Aloe vera gel/mild soap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mild soap alone
Number of subjects: 0
Study: 10210991

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment in prepubertal children
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no rhGH) in prepubertal children
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment in pubertal children
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no rhGH) in pubertal children
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no rhGH)
Number of subjects: 22
Study: 8180766

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional cholecystectomy
Number of subjects: 39
Study: 3356152

Group type: EXPERIMENTAL
Intervention: Antiepileptic drug study with centralized case validation system
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Targeted extra support for patients with known problems at entry
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Case categorization at entry
Number of subjects: 622
Study: 30045822

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 860
Study: 28131794

Group type: EXPERIMENTAL
Intervention: Brivanib
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 26201709

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo/SOC
Number of subjects: 1059
Study: 23877864

Group type: EXPERIMENTAL
Intervention: Remifentanil 4 µg/kg intravenously
Number of subjects: 80

Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg
Number of subjects: 80
Study: 20375299

Group type: EXPERIMENTAL
Intervention: GIN therapy (insulin at 2 mU . kg(‐1) . min(‐1) during surgery, decreased to 1 mU . kg(‐1) . min(‐1) for 24 hours, dextrose 20% infusion)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard therapy (conventional insulin sliding scale)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GIN therapy
Number of subjects: 52
Study: 18708248

Group type: EXPERIMENTAL
Intervention: Improved oxygen system (oxygen concentrators and pulse oximeters) introduced in five hospitals.
Number of subjects: 11000
Study: 16773643

Group type: EXPERIMENTAL
Intervention: High-force eccentric resistance training (3 days a week for 12 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard-care control
Number of subjects: 19
Study: 14668667

Group type: EXPERIMENTAL
Intervention: Picker questionnaire
Number of subjects: 2850

Group type: EXPERIMENTAL
Intervention: Patient Judgment System (PJS)
Number of subjects: 2850

Group type: EXPERIMENTAL
Intervention: Sequs
Number of subjects: 2850

Group type: EXPERIMENTAL
Intervention: Lausanne questionnaire
Number of subjects: 2850
Study: 11198135

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 9
Study: 8826226

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 0
Study: 1591737

Group type: EXPERIMENTAL
Intervention: Milacemide
Number of subjects: 0
Study: 4000324

Group type: EXPERIMENTAL
Intervention: Polysaccharide meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mono- and disaccharide meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All meals (including polysaccharide, mono- and disaccharide)
Number of subjects: 24
Study: 31786872

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with interval cytoreductive surgery
Number of subjects: 178

Group type: COMPARATOR
Intervention: Primary cytoreductive surgery alone
Number of subjects: 178
Study: 29188298

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus RT (2 cycles of gemcitabine 1000 mg/m2 on days 1, 8, and 15, and cisplatin 70 mg/m2 on day 2, followed by RT to 4500 cGy in 150 cGy twice-daily fractions over 3 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chemotherapy alone (4 cycles of gemcitabine and cisplatin)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus RT
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 120
Study: 27075990

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) consisting of three 5-minute cycles of upper limb cuff occlusion with 5-minutes of reperfusion, both 24 hours and immediately before surgery.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group received a similarly timed sham treatment.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: RIPC
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control
Number of subjects: 85
Study: 24913220

Group type: EXPERIMENTAL
Intervention: Text2Quit
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Self-reported smoking cessation
Number of subjects: 503

Group type: COMPARATOR
Intervention: Self-help material
Number of subjects: 503
Study: 22093057

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 1000 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19799810

Group type: EXPERIMENTAL
Intervention: Induction-concurrent chemoradiotherapy (IC/CCRT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Induction chemotherapy and radiotherapy (IC/RT)
Number of subjects: 400
Study: 17613561

Group type: EXPERIMENTAL
Intervention: Therapeutic intensity of ultrasound
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-intensity application of ultrasound
Number of subjects: 44
Study: 15716206

Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid therapy (40 mg weekly for 10 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (C(max) <350 cc)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (C(max) >/=350 cc)
Number of subjects: 48
Study: 12036188

Group type: EXPERIMENTAL
Intervention: Chagas' disease group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 10076773

Group type: EXPERIMENTAL
Intervention: 1:10,000 epinephrine hydrochloride
Number of subjects: 26

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 26
Study: 8719069

Group type: EXPERIMENTAL
Intervention: VIP chemotherapy (vindesine 3 mg/m2 days 1 and 8, ifosfamide 1200 mg/m2, cisplatin 30 mg/m2 days 1, 2 and 3, repeated every 4 weeks, up to six cycles)
Number of subjects: 64
Study: 2024842

Group type: EXPERIMENTAL
Intervention: Oxygen (28% oxygen by Venturi face mask)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Air (by Venturi face mask)
Number of subjects: 22
Study: 7004808

Group type: EXPERIMENTAL
Intervention: Lactose (50 g twice a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neomycin (3 g/day) plus milk of magnesia
Number of subjects: 10
Study: 31549334

Group type: COMPARATOR
Intervention: Metronidazole (M)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saccharomyces boulardii (SB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metronidazole + Saccharomyces boulardii (M + SB)
Number of subjects: 40
Study: 31610249

Group type: EXPERIMENTAL
Intervention: Whole pelvis radiotherapy (WPRT) 46Gy in 23 fractions + 15Gy single dose HDR BT
Number of subjects: 812

Group type: COMPARATOR
Intervention: Prostate-only radiotherapy (PORT) 37.5Gy in 15 fractions + 15Gy single dose HDR BT
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: WPRT
Number of subjects: 812

Group type: COMPARATOR
Intervention: PORT
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Both WPRT and PORT
Number of subjects: 812
Study: 27911263

Group type: EXPERIMENTAL
Intervention: CEUS group (n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: US group (n=45)
Number of subjects: 90
Study: 26427109

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Moxibustion (Mox)
Number of subjects: 81
Study: 23801770

Group type: EXPERIMENTAL
Intervention: 0.5 mg neostigmine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous butylscopolamine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 21
Study: 21108675

Group type: EXPERIMENTAL
Intervention: Support and education via telephone one week after surgery and face-to-face support six months after surgery
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 164
Study: 19799101

Group type: EXPERIMENTAL
Intervention: WALK+ (walking program supplemented by tasks designed to challenge balance and mobility)
Number of subjects: 31

Group type: COMPARATOR
Intervention: WALK (traditional walking program)
Number of subjects: 31
Study: 17513410

Group type: EXPERIMENTAL
Intervention: P125 (1.00 g protein . kg BW(‐1). d(‐1))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: P94 (0.75 g protein . kg BW(‐1). d(‐1))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: P63 (0.50 g protein . kg BW(‐1). d(‐1))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 22
Study: 15155598

Group type: EXPERIMENTAL
Intervention: Photo-comic intervention
Number of subjects: 658

Group type: COMPARATOR
Intervention: Placebo comic (Control)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Radio-drama (among those who recalled it)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: No recall of radio-drama (among those who did not recall it)
Number of subjects: 658
Study: 11989524

Group type: EXPERIMENTAL
Intervention: Herceptin® (various regimens and durations)
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Herceptin® (adjuvant therapy)
Number of subjects: 12000
Study: 10518855

Group type: EXPERIMENTAL
Intervention: Antimicrobial dentifrice containing 0.45% stannous fluoride
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Antitartar dentifrice containing 0.243% sodium fluoride and 5% pyrophosphate
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Antimicrobial dentifrice containing 0.24% sodium fluoride and 0.30% triclosan/copolymer
Number of subjects: 384

Group type: COMPARATOR
Intervention: Bottled distilled water (negative control)
Number of subjects: 384
Study: 7521542

Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 68

Group type: COMPARATOR
Intervention: Parenteral feeding
Number of subjects: 68
Study: 2757898

Group type: COMPARATOR
Intervention: Aspirin (SA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (FLU)
Number of subjects: 0
Study: 326303

Group type: EXPERIMENTAL
Intervention: Atenolol 4% eye drops (Tenormin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline 0-9% (control)
Number of subjects: 8
Study: 31250180

Group type: EXPERIMENTAL
Intervention: Combined model (clinical + radiomic features)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Model with only clinical features
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Model with only radiomic features
Number of subjects: 198
Study: 27993911

Group type: COMPARATOR
Intervention: Low-dose oxytocin infusion (10 U in 500 mL normal saline at 36 mL/hour for 4 hours)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin infusion plus an additional 2 U of oxytocin given over 10 min immediately after birth
Number of subjects: 59
Study: 25951636

Group type: EXPERIMENTAL
Intervention: Comprehensive Western medical treatment plus Compound Yindan Decoction (CYD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comprehensive Western medical treatment alone
Number of subjects: 60
Study: 24082369

Group type: EXPERIMENTAL
Intervention: Optimized temporary biventricular pacing
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Atrial pacing at matched heart rate
Number of subjects: 5
Study: 21896874

Group type: EXPERIMENTAL
Intervention: Small particle size CaCO(3) (13.5 μm)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Large particle size CaCO(3) (18 μm)
Number of subjects: 31
Study: 20210231

Group type: EXPERIMENTAL
Intervention: Thalidomide (150 mg orally twice daily on days 2 through 5)
Number of subjects: 52
Study: 17349809

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-PRP approximately T (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP-IPV plus PRP approximately T at separate injection sites (group B)
Number of subjects: 0
Study: 12765853

Group type: EXPERIMENTAL
Intervention: NNC‐687 (5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NNC‐687 (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NNC‐687 (15 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10912743

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 142
Study: 9313756

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 9
Study: 8453848

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg three times a day for 1 week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg) intravenously
Number of subjects: 12
Study: 3544186

Group type: EXPERIMENTAL
Intervention: Pirenzepine (10 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atropine (1 mg)
Number of subjects: 20
Study: 31904028

Group type: EXPERIMENTAL
Intervention: Radical endoscopic sinus surgery (RESS)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: RESS+Draf 3 surgery
Number of subjects: 81

Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: RESS
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: RESS+Draf 3
Number of subjects: 81
Study: 30209073

Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block administered by paramedics as early prehospital pain relief.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Scratchcards for random allocation concealment.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Scratchcards as a method of random allocation.
Number of subjects: 71
Study: 26739688

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda (180 μg weekly for 48 weeks)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a (weekly for 48 weeks)
Number of subjects: 163
Study: 24996857

Group type: EXPERIMENTAL
Intervention: Maxillary advancement (n=51)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Bimaxillary procedure (n=102)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Mandibular setback (n=38)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: All surgical approaches
Number of subjects: 191
Study: 22622860

Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 20691418

Group type: EXPERIMENTAL
Intervention: Green laser (532‐nm wavelength)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Infrared laser (810‐nm wavelength)
Number of subjects: 30
Study: 19014023

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with distilled water
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with 17% EDTAC
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with 1% sodium hypochlorite
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with 2% chlorhexidine
Number of subjects: 36
Study: 12661258

Group type: EXPERIMENTAL
Intervention: Organ-saving operations
Number of subjects: 0
Study: 9875193

Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate
Number of subjects: 6

Group type: COMPARATOR
Intervention: General use of zinc sulfate
Number of subjects: 6
Study: 7913205

Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion (2.4 mU/kg/min for 2 minutes followed by 10 minutes off)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous insulin infusion (0.4 mU/kg/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous insulin infusion
Number of subjects: 6
Study: 2575014

Group type: EXPERIMENTAL
Intervention: CV 205-502 (CV)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30399036

Group type: EXPERIMENTAL
Intervention: Confirmed TB (MLR 0.407, IQR 0.378-0.675)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: MLR cutoff value of 0.378
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Post-TB treatment MLR
Number of subjects: 160
Study: 28673251

Group type: EXPERIMENTAL
Intervention: Enhanced linkage to HIV care intervention
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard-of-care (paper-based referrals)
Number of subjects: 600
Study: 25659828

Group type: EXPERIMENTAL
Intervention: Adjunctive zonisamide (target dose 8 mg/kg/day; maximum 500 mg/day)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Adjunctive zonisamide
Number of subjects: 179
Study: 23571365

Group type: EXPERIMENTAL
Intervention: Enhanced daily cleaning of ICU room surfaces
Number of subjects: 132

Group type: COMPARATOR
Intervention: Routine care in control rooms
Number of subjects: 132
Study: 21983354

Group type: EXPERIMENTAL
Intervention: Epaxal(®) 0.25 mL
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Epaxal(®) 0.5 mL
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Havrix(®) Junior
Number of subjects: 360

Group type: COMPARATOR
Intervention: All vaccines
Number of subjects: 360

Group type: COMPARATOR
Intervention: All study vaccines
Number of subjects: 360
Study: 19233181

Group type: COMPARATOR
Intervention: Low-dose celecoxib (200 mg twice daily)
Number of subjects: 1660

Group type: COMPARATOR
Intervention: High-dose celecoxib (400 mg twice daily)
Number of subjects: 1660

Group type: COMPARATOR
Intervention: Celecoxib (both doses)
Number of subjects: 1660
Study: 16309928

Group type: EXPERIMENTAL
Intervention: MSM 3g twice a day for 12 weeks (6g/day total)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15639691

Group type: EXPERIMENTAL
Intervention: multidose dry powder inhaler (mDPI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: capsule dry powder inhaler (cDPI)
Number of subjects: 80
Study: 11411192

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 51
Study: 9421103

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 480 mg daily (Group-1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no Tamoxifen, Group-2)
Number of subjects: 20
Study: 8273245

Group type: EXPERIMENTAL
Intervention: Steroid lotion with additives
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plain steroid lotion
Number of subjects: 60
Study: 3432562

Group type: EXPERIMENTAL
Intervention: BN 52063
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31253613

Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS) comprising an oral sensor tablet coencapsulated with an antipsychotic (aripiprazole, olanzapine, quetiapine, or risperidone), non-medicated wearable patch, mobile application, and web-based dashboard.
Number of subjects: 0
Study: 28087928

Group type: EXPERIMENTAL
Intervention: 3 months of weekly directly observed therapy
Number of subjects: 7061

Group type: COMPARATOR
Intervention: 9 months of daily self-administered therapy
Number of subjects: 7061
Study: 24968251

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) with 5 or 10 mg transdermal T patch daily for 12 months
Number of subjects: 13
Study: 24308044

Group type: EXPERIMENTAL
Intervention: Higher physical activity group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower physical activity group
Number of subjects: 0
Study: 22075320

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system (RAS) inhibitors
Number of subjects: 25

Group type: COMPARATOR
Intervention: Historical untreated controls
Number of subjects: 25
Study: 19635169

Group type: EXPERIMENTAL
Intervention: Oral heme iron polypeptide (HIP; Proferrin ES) - 1 tablet twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow-release ferrous sulphate - 1 tablet twice daily (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (HIP and control)
Number of subjects: 0
Study: 16684267

Group type: EXPERIMENTAL
Intervention: 500 mg of methanolic extract of L. pacari (n = 55)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (n = 45)
Number of subjects: 100
Study: 15087552

Group type: EXPERIMENTAL
Intervention: Intensive exercise therapy with immobilization of the unimpaired arm (forced use)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intensive exercise therapy without immobilization of the unimpaired arm (forced use)
Number of subjects: 56